Is Merck an attractive target for activists?
At least one hedge fund firm thinks so.
In its second-quarter letter, dated August 17 and obtained by Institutional Investor, Suvretta Capital Management — which is not an activist hedge fund — makes the case for the drug giant winding up in the cross-hairs of the activist set as part of its investment thesis for the stock.
“We